ShockWave Medical, Inc. (NASDAQ:SWAV) Stock Holdings Lessened by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. reduced its position in shares of ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating) by 3.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,375 shares of the company’s stock after selling 170 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in ShockWave Medical were worth $836,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Jennison Associates LLC boosted its holdings in ShockWave Medical by 98.5% in the first quarter. Jennison Associates LLC now owns 433,534 shares of the company’s stock worth $89,898,000 after purchasing an additional 215,142 shares in the last quarter. Invesco Ltd. boosted its holdings in ShockWave Medical by 16.0% during the first quarter. Invesco Ltd. now owns 1,398,211 shares of the company’s stock valued at $289,933,000 after acquiring an additional 192,525 shares during the period. Polar Asset Management Partners Inc. acquired a new position in shares of ShockWave Medical during the first quarter valued at about $20,881,000. Eagle Asset Management Inc. acquired a new position in shares of ShockWave Medical during the first quarter valued at about $19,154,000. Finally, Vanguard Group Inc. raised its position in shares of ShockWave Medical by 2.1% during the first quarter. Vanguard Group Inc. now owns 3,311,557 shares of the company’s stock valued at $686,685,000 after buying an additional 67,789 shares during the last quarter. 95.40% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ShockWave Medical

In other ShockWave Medical news, CFO Dan Puckett sold 1,100 shares of ShockWave Medical stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $292.21, for a total value of $321,431.00. Following the sale, the chief financial officer now directly owns 39,938 shares in the company, valued at approximately $11,670,282.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Dan Puckett sold 1,100 shares of ShockWave Medical stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $292.21, for a total value of $321,431.00. Following the completion of the transaction, the chief financial officer now owns 39,938 shares of the company’s stock, valued at approximately $11,670,282.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Frank T. Watkins sold 3,000 shares of ShockWave Medical stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $291.87, for a total transaction of $875,610.00. Following the completion of the transaction, the director now directly owns 12,796 shares of the company’s stock, valued at approximately $3,734,768.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,450 shares of company stock worth $8,166,829. Insiders own 3.90% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Morgan Stanley increased their price target on shares of ShockWave Medical from $255.00 to $290.00 and gave the stock an “equal weight” rating in a research report on Tuesday, October 11th. Oppenheimer cut shares of ShockWave Medical from a “market perform” rating to an “underperform” rating and set a $165.00 price target for the company. in a research report on Tuesday, September 6th. Piper Sandler increased their target price on ShockWave Medical from $278.00 to $338.00 and gave the company an “overweight” rating in a research note on Monday, August 29th. Bank of America upped their price target on ShockWave Medical from $260.00 to $310.00 in a research note on Monday, November 7th. Finally, Canaccord Genuity Group lifted their price target on shares of ShockWave Medical from $232.00 to $256.00 and gave the stock a “buy” rating in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $263.00.

ShockWave Medical Stock Down 1.4 %

Shares of SWAV stock opened at $243.19 on Tuesday. The company has a current ratio of 7.29, a quick ratio of 6.02 and a debt-to-equity ratio of 0.04. ShockWave Medical, Inc. has a 1 year low of $113.36 and a 1 year high of $320.54. The firm’s fifty day moving average price is $275.76 and its two-hundred day moving average price is $230.78. The firm has a market capitalization of $8.79 billion, a P/E ratio of 104.37 and a beta of 1.03.

ShockWave Medical Company Profile

(Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Featured Articles

Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating).

Institutional Ownership by Quarter for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.